1. Introduction {#sec1-molecules-25-03116}
===============

The liver is primarily responsible for alcohol metabolism in the human body and as this is the case, it is vulnerable to alcohol-related injuries \[[@B1-molecules-25-03116]\]. According to literature, chronic alcohol consumption causes liver cell inflammation which triggers an immune response through recognition of damage-associated molecular patterns (DAMPs). DAMPs signal damage or necrosis through transmembrane toll-like receptors (TLRs), a class of proteins that play a key role in the innate immune system \[[@B2-molecules-25-03116]\]. TLRs are single-pass membrane-spanning receptors usually expressed on sentinel cells such as macrophages and dendritic cells and recognized structurally conserved molecules \[[@B2-molecules-25-03116],[@B3-molecules-25-03116]\]. Once recognition occurs, TLRs activate common signaling pathways that activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a key regulator of inflammatory gene expression. This results in the activation of numerous physiological responses: cytokine tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interlukin-1 (IL-l), IL-6, IL-12, cell adhesion molecules, such as vascular cell adhesion molecule **1** (VCAM-1) and intercellular adhesion molecule **1** (ICAM-1), reactive oxygen species (ROS), inducible nitric oxide synthase (iNOS), and cyclooxygenase II (COX-II) \[[@B1-molecules-25-03116],[@B3-molecules-25-03116]\]. These molecules elicit the production of prostaglandin E~2~ (PGE~2~), chemokines, and various co-stimulatory molecules which play important roles in the pathogenesis of liver cell inflammation \[[@B1-molecules-25-03116]\]. Moreover, the activity of monocytes and neutrophils improve and migrate to inflammation sites and create a cytotoxic environment by releasing noxious chemicals, including ROS, nitrogen species, and various proteinases, which are destructive to both pathogens and host cells. Liquefaction induction of the surrounding hepatic tissue was also observed, resulting in liver cell damage which led to heat, swelling, pain, and loss of tissue function. This is reflected by elevated serum levels of bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) \[[@B1-molecules-25-03116],[@B3-molecules-25-03116]\].

On the other hand, ROS are naturally produced by living organisms through negative cellular metabolism \[[@B4-molecules-25-03116]\]. At intermediate concentrations, ROS improve physiological cell processes. However, at high ones, ROS adversely modify cell contents as lipid malondialdehyde (MDA), proteins, and deoxyribonucleic acid (DNA) \[[@B4-molecules-25-03116]\]. ROS are classified as free radicals, where superoxide anion (O~2~^−^), hydroxyl radical (OH^−^), and hydrogen peroxide (H~2~O~2~) are considered physiologically significant ROS \[[@B4-molecules-25-03116]\]. The human body naturally contains a variety of antioxidants which counterbalance the effect of ROS such as catalase, glutathione peroxidase (GSH-Px), vitamins (A, C and E), β-carotene, and glutathione (GSH) \[[@B4-molecules-25-03116]\]. As previously indicated, direct liver cell damage that occurs during chronic alcohol consumption is caused by free radicals \[[@B5-molecules-25-03116]\]. In a healthy individual with no liver damage, free radicals are quickly scavenged by natural protective antioxidants (GSH, GSH-Px, vitamins A and E), yet in chronic alcohol consumption individuals, levels of these naturally occurring antioxidants are reduced, GSH being the most affected \[[@B5-molecules-25-03116]\]. Consequently, chronic inflammation progress by ROS could cause organ dysfunction, especially when this process targets important organs like liver \[[@B4-molecules-25-03116]\]. Detecting liver function tests (bilirubin, AST, ALT, and ALP), pro-inflammatory markers (IL-1β, IL-6, IL-10, TNF-α, CRP, nitric oxide (NO), ICAM-1, VCAM-1, and COX-II), oxidative stress marker levels, and antioxidant tests (MDA, H~2~O~2~, GSH-Px, catalase, GSH, and total antioxidant capacity (TAC)) are important steps to determine how much an organ is damaged \[[@B1-molecules-25-03116]\].

Liver disease is a life-threatening disease with elevated mortality rates \[[@B6-molecules-25-03116]\]. Current approaches to treatment, including drug therapy and liver transplantation, feature limited efficacy and risky complications \[[@B6-molecules-25-03116]\]. These concerns have stimulated the search for alternative safe and effective drugs, especially natural drugs, due to their potential in treatment of various forms of hepatopathy \[[@B7-molecules-25-03116]\]. *Premna odorata* is an ethnobotanical plant native to different tropical regions. As a folk medicine, a decoction of its leaves has been used as a febrifuge, diuretic, carminative, and to treat vaginal irritation, abdominal pains, coughing, and dysentery \[[@B8-molecules-25-03116]\]. A limited number of investigations have been carried out on the *Premna* genus, particularly on the *Premna odorata* species, where iridoids, phenylethanoids, flavonoids, and acylated rhamnopyranosides were preliminary described as its main active constituents \[[@B9-molecules-25-03116],[@B10-molecules-25-03116],[@B11-molecules-25-03116],[@B12-molecules-25-03116]\]. Additional studies also addressed their anti-inflammatory, cytotoxic, and anti-tuberculosis effects \[[@B9-molecules-25-03116],[@B13-molecules-25-03116],[@B14-molecules-25-03116],[@B15-molecules-25-03116],[@B16-molecules-25-03116]\]. However, their hepatoprotective potential is yet to be explored. Therefore, this study investigated the crude extract and different fractions of the plant leaves; metabolomics profiling using liquid chromatography/high-resolution electrospray ionization mass spectroscopy (LC--HRESIMS), in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties for the dereplicated metabolites, ROS scavenger activity, and the possible hepatic cellular treatment effects in alcohol-inflamed liver female Wistar albino rats.

2. Results {#sec2-molecules-25-03116}
==========

2.1. Metabolomic Analysis {#sec2dot1-molecules-25-03116}
-------------------------

Chemical profiling of the secondary metabolites of *Premna odorata* leaves using LC--HRESIMS for dereplication purposes resulted in the characterization of a variety of constituents, including sterols, triterpenes, fatty acids, iridoids, flavones, and phenylethanoids ([Table 1](#molecules-25-03116-t001){ref-type="table"}, [Figure 1](#molecules-25-03116-f001){ref-type="fig"}). From the metabolomics data, the ion at mass-to-charge ratio *(m/z*) 433.1361 corresponding to the suggested molecular formula C~21~H~20~O~10~ was dereplicated as vitexin (**1**) \[[@B9-molecules-25-03116],[@B17-molecules-25-03116]\], which was formerly reported in *Premna odorata*. Two acylated iridoid glycosides with the molecular formula C~39~H~44~O~20~ and C~30~H~38~O~17~ were characterized as premnoside A (**2**) and 6-*O*-α-L-(2''-O-trans-caffoyl) rhamnopyranosyl catalpol (**3**) from the ions at *m/z* 833.2746 and 671.1910, respectively, which were previously reported in *Premna odorata* \[[@B11-molecules-25-03116],[@B12-molecules-25-03116]\]. Furthermore, the ion at *m/z* 577.1969 with the corresponding predicted molecular formula C~35~H~60~O~6~ was dereplicated as the steroidal glycoside daucosterol (**4**), which was earlier isolated from *Premna japonica*, whereas herein, it is reported from the *Premna odorata* plant for the first time \[[@B18-molecules-25-03116]\]. Additional sterols, triterpenes, fatty acids, iridoids, phenylethanoids, and flavone-related compounds which were formally isolated from *Premna odorata* leaves were also characterized as compounds **5**--**7**, **9**--**11**, **13**--**16**, **18**, **19**--**22**, and **24**--**26** based on the ions and the corresponding predicted molecular formulas ([Table 1](#molecules-25-03116-t001){ref-type="table"}, [Figure 1](#molecules-25-03116-f001){ref-type="fig"}) \[[@B8-molecules-25-03116],[@B9-molecules-25-03116],[@B10-molecules-25-03116],[@B11-molecules-25-03116],[@B19-molecules-25-03116]\]. The ions at *m/z* 669.1634 and 685.2780 with the predicted molecular formulas C~31~H~40~O~16~ and C~31~H~40~O~17~ were dereplicated as the iridoid glycosides 6-*O*-α-L-(2''-*O*-trans-p-methoxycinnamoyl) rhamnopyranosyl catalpol (**8)** and 6-*O*-α-L-(4''-*O*-trans-feruloyl) rhamnopyranosyl catalpol (**12**) \[[@B18-molecules-25-03116]\], which were first reported in the *Premna* genus. Likewise, iridoids with the molecular formula C~42~H~64~O~20~ and C~45~H~58~O~24~ were identified as premnaodoroside D (**23**) \[[@B20-molecules-25-03116]\] and premcoryoside (**27**) \[[@B21-molecules-25-03116]\], which were reported for the first time in the *Premna* genus. Furthermore, the ions at *m/z* 277.1807, and 489.2793 with the suggested molecular formulas C~18~H~30~O~2~ and C~30~H~48~O~5~ were identified as the unsaturated fatty acid linolenic acid and the pentacyclic triterpene arjunolic acid (**13** and **28**, respectively) \[[@B22-molecules-25-03116]\]. It is worth mentioning that based on dereplication, sterols, triterpenes, and the fatty acid were predominantly in the n-hexane (n-hex) fraction, while iridoids, flavones, and phenylethanoids were the major metabolites in the dichloromethane (DCM), ethyl acetate (EtOAC), and n-butanol fractions ([Table 1](#molecules-25-03116-t001){ref-type="table"}, [Figure 1](#molecules-25-03116-f001){ref-type="fig"}).

2.2. In Silico ADMET Properties for the Crude Extract of Different Premna odorata Metabolites {#sec2dot2-molecules-25-03116}
---------------------------------------------------------------------------------------------

In silico predicted ADMET profiling of the dereplicated secondary metabolites using PreADMET program version 2.0 showed that flavones (vitexin (**1**), acacetin (**10**), diosmetin (**18**), luteolin, and apigenin (**25**--**26**) had low to middle absorption to the blood--brain barrier (BBB), moderate to high human intestinal absorption (HIA), weak to strong plasma protein binding (PPB), moderate skin permeability (SP), middle permeability to heterogeneous human epithelial colorectal adenocarcinoma Caco-2 cells and the Madin--Darby Canine Kidney (MDCK) cell model. Additionally, all flavones inhibited cytochrome P~450~-2C~19~ (CYP~2~C~19~), CYP~2~C~9~, and CYP~3~A~4~ with no effect on the permeability glycoprotein (Pgp) ([Table 2](#molecules-25-03116-t002){ref-type="table"}). Toxicity screening results using PreADMET for flavone aglycones showed mutagenicity using the Ames test except for **1**. Moreover, flavones showed potential rat and rodent carcinogenicity, except for **1**, which showed carcinogenicity in rats only. Furthermore, the human Ether-à-go-go-Related Gene (hERG) inhibition is of moderate to high risk ([Table 3](#molecules-25-03116-t003){ref-type="table"}). Moreover; iridoids (premnoside A and 6-*O*-α-L-(2''-*O*-trans-caffoyl) rhamnopyranosyl catalpol (**2**--**3**), premnoside C, D, H, and 6-*O*-α-L-(2''-*O*-trans-methoxycinnamoyl) rhamnopyranosyl catalpol (**5**--**8**), premnoside G and 6-*O*-α-L-(4''-*O*-trans-feruolyl) rhamnopyranosyl catalpol (**11**--**12**), premnoside E and F (**15**--**16**), premnaodoroside A--D and premnoside D (**19**--**23**), premcoryoside **27**) and phenylethanoid verbascoside (**14**) had low absorption to the BBB, except for compounds **11**, **15**, and **16** which showed moderate absorption, poor HIA, except for compounds **11**, **15**, and **16** which showed moderate results, weak PPB, poor SP, middle Caco-2, MDCK permeability. Furthermore, all iridoids inhibited Pgp, CYP~2~C~19~, CYP~2~C~9~, and CYP~3~A~4~ ([Table 2](#molecules-25-03116-t002){ref-type="table"}). Toxicity screening results using PreADMET for iridoids and phenylethanoids showed no mutagenicity using the Ames test, except for compounds **19**, **21**, and **23** which showed positive mutagenicity with the TA100-NA strain and negative mutagenicity with the other strains used. Moreover, iridoids and phenylethanoids showed no potential rat carcinogenicity except against rodents. Also, hERG inhibition was ambiguous, except for compounds **8** and **15**--**16**, which were of high risk ([Table 3](#molecules-25-03116-t003){ref-type="table"}). The sterols, triterpenes, and fatty acids (daucosterol (**4**), stigmasterol (**9**), β-sitosterol (**13**), linolenic acid (**17**), β-amyrin (**24**), arjunolic acid (**28**) had middle to strong absorption to the BBB, high HIA, strong PPB, good SP, middle Caco-2, MDCK permeability; furthermore, all of them inhibited Pgp, CYP~2~C~9~, and CYP~3~A~4~ ([Table 2](#molecules-25-03116-t002){ref-type="table"}). Toxicity screening results showed no mutagenicity using the Ames test, except for compound **17**. Moreover, these compounds showed potential rat and rodent carcinogenicity, except for compounds **4** and **13**, which showed carcinogenicity against rodents only. Furthermore, hERG inhibition is of low to moderate risk ([Table 3](#molecules-25-03116-t003){ref-type="table"}).

HERG: human Ether-à-go-go-Related Gene. The Ames test is a simple method of testing mutagenicity of a compound. PreADMET predicts toxicity for TA98, TA100, and TA1535, which are often used in the Ames test. The prediction result is positive or negative. Rodent carcinogenicity is a toxicity that causes cancer in the body. PreADMET predicts the result from its model, which is built upon the data of the National Toxicology Program (NTP) and the United States Food and Drug Administration (US FDA), which are the results of the 2-year-long in vivo carcinogenicity tests of mice and rats. Negative prediction indicates clear evidence of carcinogenic activity, and positive prediction shows no evidence of carcinogenic activity. The hERG is a gene that codes for a protein known as K~v~11.1, the alpha subunit of a potassium ion channel. This ion channel is best known for its contribution to the electrical activity of the heart. The hERG channel mediates the repolarizing I~Kr~ current in the cardiac action potential, which helps coordinate the heart's beating.

2.3. In Vitro Measurement of Total Reactive Oxygen Species (ROS) {#sec2dot3-molecules-25-03116}
----------------------------------------------------------------

Various *Premna odorata* extracts (crude, defatted crude, and n-hex) were screened for their ability to scavenge the ROS in the Hep G2 human liver cancer cell line at 100 μL using the Reactive Oxygen Species Assay (Beyotime Institute of Biotechnology) ([Figure 2](#molecules-25-03116-f002){ref-type="fig"}). The results showed that the treatment with all the extracts significantly decreases the Hep G2 ROS content, reflecting activities of their antioxidants. Silymarin with defined antioxidant activity was used as a standard reference drug at a 100 μL dose.

2.4. Acute Toxicity {#sec2dot4-molecules-25-03116}
-------------------

In this study, the acute toxicity test of the crude, defatted crude, and n-hex extracts showed no signs of toxicity up to 5 g/kg body weight (b.w.); they were considered safe. Therefore, all extracts were investigated at a dose of 1/10 (500 mg/kg b.w.) in the alcohol-inflamed liver of female Wistar albino rats.

2.5. Potential Effects of Premna odorata Extracts in Liver Function Tests {#sec2dot5-molecules-25-03116}
-------------------------------------------------------------------------

In response to the alcohol-inflamed liver, bilirubin, AST, ALT, and ALP showed a significant increase in their serum levels with the percentage reaching 65.88%, 108.53%, 33.05%, and 34.04%, respectively, when compared to the negative control group ([Table 4](#molecules-25-03116-t004){ref-type="table"}). Treatment of alcohol-inflamed liver rats with crude, defatted crude, n-hex extracts showed a significant decrease in the bilirubin, AST, ALT, and ALP levels in all treated groups when compared to the silymarin positive control group. The crude leave extract showed the highest percentage of improvement for AST (143.23%) and ALP (48.47%). While bilirubin showed a significant improvement upon treatment with crude and n-hex extracts (58.11%), the defatted crude extract showed the best improvement of the ALT level (66.68%) in all treated groups ([Table 4](#molecules-25-03116-t004){ref-type="table"}).

2.6. Potential Effects of Premna odorata Extracts on Oxidative Stress Markers, and Antioxidant {#sec2dot6-molecules-25-03116}
----------------------------------------------------------------------------------------------

In response to the alcohol-inflamed liver state, the MDA level showed a significant increase (42.97%) when compared to the negative control group. The GSH and TAC had a significant decrease of 27.42% and 38.46%, respectively ([Table 4](#molecules-25-03116-t004){ref-type="table"}). Treatment of alcohol-inflamed liver rats with crude, defatted crude, n-hex extracts showed a significant increase in the GSH and TAC levels in all treated groups compared to the silymarin positive control group ([Table 4](#molecules-25-03116-t004){ref-type="table"}). Defatted crude and n-hex extracts showed the highest percentage of improvement for the GSH (50.32%) and TAC (42.30%). MDA showed a significant decrease in all treated groups, whereas the crude extract showed the best amelioration −71.07% ([Table 4](#molecules-25-03116-t004){ref-type="table"}).

2.7. Potential Effects of Premna odorata Extracts on Inflammatory Markers and Adhesion Molecules {#sec2dot7-molecules-25-03116}
------------------------------------------------------------------------------------------------

In response to the alcohol-inflamed liver state, CRP, TNF-α, ICAM-1, and VCAM-1 parameters showed a significant increase in their levels, 86.96%, 98.49%, 114.54%, and 51.72%, respectively, when compared to the negative control group ([Table 4](#molecules-25-03116-t004){ref-type="table"}). Treatment of alcohol-inflamed liver rats with crude, defatted crude, n-hex extracts showed a significant decrease in CRP, TNF-α, VCAM-1, and ICAM-1 when compared to the silymarin positive control group ([Table 2](#molecules-25-03116-t002){ref-type="table"}). The n-hex fraction recorded the highest percentage of improvement for CRP (86.20%) and ICAM-1 (96.36%). The defatted crude extract showed the highest percentage of amelioration for TNF-α (102.56%). VCAM-1 was improved upon treatment with defatted crude and n-hex extracts (41.37%) ([Table 4](#molecules-25-03116-t004){ref-type="table"}).

2.8. Histopathological Investigation of Liver {#sec2dot8-molecules-25-03116}
---------------------------------------------

The histological investigation of liver sections supported the biochemical results ([Figure 3](#molecules-25-03116-f003){ref-type="fig"}). Liver sections for the control rat group showed normal lobular architecture and normal hepatic cells with a well-preserved cytoplasm and a well-defined nucleus ([Figure 3](#molecules-25-03116-f003){ref-type="fig"}A). Alcohol-inflamed liver (positive control) showed a necrobiotic change of the hepatocytes, including congestion of the central vein and hepatic sinusoids, cytoplasmic vacuolization of hepatocytes, portal edema, and focal hepatic necrosis associated with inflammatory cell infiltration ([Figure 3](#molecules-25-03116-f003){ref-type="fig"}B--D). Treatment of alcohol-inflamed liver rats with *Premna odorata* extracts (crude, defatted crude, and n-hex) ([Figure 3](#molecules-25-03116-f003){ref-type="fig"}E--I) showed positive results for all extracts in which focal tubular necrosis associated with inflammatory cell infiltration was minimum, where the crude extract was the most active followed by the defatted crude and the n-hex extracts. The slight congestion of hepatic sinusoids was also observed. The silymarin-treated group ([Figure 3](#molecules-25-03116-f003){ref-type="fig"}K--L) showed a slightly hydropic regeneration of hepatocytes and focal hepatic hemorrhage.

3. Discussion {#sec3-molecules-25-03116}
=============

Metabolic profiling of *Premna odorata* dereplicated 28 metabolites from the various fractions of the crude leave extract. The identified metabolites belonged to various chemical classes, including iridoids (monoterpenes), triterpenes, flavones, and phenylethanoids. According to literature, pharmacokinetic parameters of compounds, such as absorption, distribution, metabolism, excretion, and toxicity (ADMET), are important in order to determine the potential success of a compound for therapeutic use. Some important chemical descriptors correlate well with ADMET properties, for instance, HIA as a primary determinant of oral absorption of a fraction. The distribution of each compound in the human body depends on many factors, such as permeability of the BBB, Caco-2, MDCK, SP, and PPB. Similarly, the metabolism and excretion of most drugs also depend on many factors, like CYP~2~C~19~, CYP~2~C~9~, CYP~3~A~4~, and Pgp. In silico predicted ADMET profiling of the dereplicated secondary metabolites present in *Premna odorata* leaves showed that flavones (vitexin (**1**), acacetin (**10**), diosmetin (**18**), luteolin, and apigenin (**25**--**26**) had low to middle absorption to the BBB, moderate to high HIA, weak to strong PPB, moderate SP, and middle Caco-2 and MDCK permeability. Furthermore, all flavones inhibited CYP~2~C~19~, CYP~2~C~9~, and CYP~3~A~4~ and had no significant effect on Pgp ([Table 2](#molecules-25-03116-t002){ref-type="table"}). Toxicity screening results from PreADMET for the flavone aglycones showed mutagenicity using the Ames test, except for **1**. Moreover, all flavones showed potential rat and rodent carcinogenicity, except for **1**, which only showed carcinogenicity against rats. Furthermore, a moderate to high risk of hERG inhibition was predicted ([Table 3](#molecules-25-03116-t003){ref-type="table"}). The iridoids (premnoside A and 6-*O*-α-L-(2''-*O*-trans-caffoyl) rhamnopyranosyl catalpol (**2**--**3**), premnoside C, D, H, and 6-*O*-α-L-(2''-*O*-trans-methoxycinnamoyl) rhamnopyranosyl catalpol (**5**--**8**), premnoside G and 6-*O*-α-L-(4''-*O*-trans-feruolyl) rhamnopyranosyl catalpol (**11**--**12**), premnoside E, F (**15**--**16**), premnaodoroside A--D and premnoside D (**19**--**23**), premcoryoside (**27**) and phenylethanoid verbascoside (**14**) had low absorption to the BBB, except for **11**, **15**, and **16**, which showed moderate absorption, poor HIA, except for **11**, **15**, **16**, which showed moderate results, weak PPB, poor SP, and moderate Caco-2 and MDCK permeability. Furthermore, all iridoids inhibited Pgp, CYP~2~C~19~, CYP~2~C~9~, and CYP~3~A~4~ ([Table 2](#molecules-25-03116-t002){ref-type="table"}). Toxicity screening results from PreADMET for the iridoids showed no mutagenicity using the Ames mutagenicity test, except for **19**, **21**, and **23**, which showed positive mutagenicity for the TA100-NA strain and negative mutagenicity for the other strains used. Moreover, iridoids and phenylethanoids showed no potential rat carcinogenicity except against rodents. Furthermore, hERG inhibition was ambiguous, except for **8**, and **15**--**16** were of high risk ([Table 3](#molecules-25-03116-t003){ref-type="table"}). The sterols, triterpenes, and fatty acids (daucosterol (**4**), stigmasterol (**9**), β-sitosterol (**13**), linolenic acid (**17**), β-amyrin (**24**), arjunolic acid (**28**)) had moderate to strong absorption to the BBB, high HIA, strong PPB, good SP, middle Caco-2, MDCK permeability, and all inhibited Pgp, CYP~2~C~9~, and CYP~3~A~4~ ([Table 2](#molecules-25-03116-t002){ref-type="table"}). Toxicity screening results showed no mutagenicity using the Ames mutagenicity test, except for **17**. Moreover, these compounds showed potential rat and rodent carcinogenicity, except for **4** and **13**, which showed mutagenicity against rodents only. Furthermore, hERG inhibition is of low to moderate risk ([Table 3](#molecules-25-03116-t003){ref-type="table"}). The results of in silico screening highlight that *Premna odorata* metabolites theoretically are potentially highly bioactive. These features are reflected by their low plasma concentrations due to their extensive cellular uptake \[[@B24-molecules-25-03116]\]. Tight regulation of the compound plasma concentrations was accomplished through binding to serum albumin \[[@B25-molecules-25-03116]\], which lowers plasma concentrations of unbound bioactive compounds, while offering a storage system for delayed release into the plasma. In addition, albumin-bound compounds are more stable against oxygen-dependent degradation, resulting in prolongation of their biological availability and further extension of their plasma's half-life. This response would protect target tissues from high-level uptake of compounds, which might trigger a toxic reaction in cells \[[@B25-molecules-25-03116]\]. Indeed, prolonged release of these compounds from plasma proteins would ensure a more constant rate of cellular uptake \[[@B26-molecules-25-03116]\]. On the other hand, the ADME properties of these compounds increased their toxicity and carcinogenicity. Generally, higher lipophilicity of compounds leads to increased metabolism and poor absorption along with an increased probability of binding to undesired hydrophobic macromolecules, thereby increasing the potential for toxicity \[[@B27-molecules-25-03116]\] ([Table 2](#molecules-25-03116-t002){ref-type="table"} and [Table 3](#molecules-25-03116-t003){ref-type="table"}).

Literature indicated there is a relationship between liver disease and heavy alcohol consumption, as liver is the primary site of alcohol metabolism \[[@B28-molecules-25-03116]\]. There are two pathways for alcohol metabolism in the liver \[[@B29-molecules-25-03116]\]. The first is the alcohol dehydrogenase (ADH) pathway, which converts alcohol through oxidation processes to acetaldehyde which was found to be highly toxic to the body even in low concentrations. The second, the microsomal enzyme oxidizing system (MEOS) pathway that oxidizes alcohol to acetaldehyde by cytochrome P~450~2E~1~, or CYP~2~E~1~. In the latter, activation increases ROS production. Unfortunately, an increase in alcohol consumption also activates the MEOS pathway, resulting in the increased ROS production \[[@B29-molecules-25-03116]\]. Normally, ROS are quickly scavenged by natural protective antioxidants (GSH, GSH-Px, vitamins A and E), but chronic alcohol consumption diminishes antioxidant levels and renders liver cells more susceptible to free radical-induced injuries \[[@B5-molecules-25-03116]\]. This destructive interaction with vital cell constituents potentially causes cell death, resulting in the sequential degradation of cell membranes by a lipid peroxidation process \[[@B5-molecules-25-03116]\]. Consequently, chronic alcohol consumption causes severe liver cell inflammation \[[@B5-molecules-25-03116]\], which results in activation of the NF-κB pathway, increasing the production of TNF-α, CRP, IL-l, IL-6 and IL-12, VCAM-1 and ICAM-1, ROS, iNOS, and COX-II \[[@B1-molecules-25-03116],[@B3-molecules-25-03116]\]. These molecules together elicit the production of PGE~2~, chemokines, and various co-stimulatory molecules, which play important roles in the pathogenesis of liver cell inflammation \[[@B1-molecules-25-03116]\].

Metabolic profiling of the crude *Premna odorata* leave extract dereplicated various anti-inflammatory and antioxidants compounds. Vitexin (**1**) showed significant inhibition to TNF-α and NO \[[@B30-molecules-25-03116]\], acacetin (**10**) and apigenin (**26**) inhibited expression of ICAM-1, VCAM-1, and selective inhibition of prostaglandin synthesis and IL-6, 8 production \[[@B23-molecules-25-03116],[@B31-molecules-25-03116]\]. Diosmetin (**10**) prevented the generation of intracellular ROS and the formation of MDA, increased the effects of the intracellular antioxidant enzymes superoxide dismutase (SOD), catalse (CAT), and GH-Px, and suppressed the iNOS activity \[[@B32-molecules-25-03116]\]. Diosmetin also exerted an anti-inflammatory effect by reducing NO production and TNF-α release, reduced the enzyme activities of COX-II and PGE~2~, and blocked the NF-κB signaling pathway \[[@B32-molecules-25-03116]\]. Luteolin (25) also blocked the NF-κB signaling pathway and VCAM-1 expression \[[@B33-molecules-25-03116]\]. Moreover, the crude *Premna odorata* leave extract contained iridoids which mainly acylated with aromatic acids (coumaric, P-methoxy cinnamic, caffeic, or ferulic) ([Table 1](#molecules-25-03116-t001){ref-type="table"}, [Figure 1](#molecules-25-03116-f001){ref-type="fig"}), and aliphatic dimer iridoids (**2**--**3**, **5**--**8**, **11**--**12**, **15**--**16**, **19**--**23**, **27**), both of which prevented the generation of ROS and MDA, increased the activity of SOD, CAT, and GH-Px, and suppressed the iNOS activity. Furthermore, they reduced TNF-α release and the enzyme activities of COX-II and PGE~2~ and blocked the NF-κB signaling pathway \[[@B34-molecules-25-03116],[@B35-molecules-25-03116]\]. Furthermore, the crude *Premna odorata* extract contained daucosterol (**4**), stigmasterol (**9**), β-sitosterol (**13**), linolenic acid (**17**), β-amyrin (**24**), and arjunolic acid (**28**) and was reported to block the NF-κB signaling pathway \[[@B36-molecules-25-03116],[@B37-molecules-25-03116],[@B38-molecules-25-03116]\] ([Table 1](#molecules-25-03116-t001){ref-type="table"}, [Figure 1](#molecules-25-03116-f001){ref-type="fig"}). The reported data, ADMET, and ROS antioxidant scavenger activities against the content of various *Premna odorata* extracts ([Figure 2](#molecules-25-03116-f002){ref-type="fig"}) encourage further in-depth investigation of the plant extract's effect on an inflamed liver. In this study, the hepatic treatment potential of the crude extract of *Premna odorata* leaves and its fractions (crude, defatted total, n-hex) were investigated on the alcohol-inflamed liver of female Wistar albino rats. The different fractions were chosen according to the obtained crude extract weight 200g/3kg dried leaves and its different fractions (n-hexane, dichloromethane, ethyl acetate, and n-butanol, 20, 3, 5, 70 g/3kg dried leaves, respectively) and focusing on the distribution of iridoids, flavones, and polyphenolic metabolites according to the LC--HRESIMS profiling ([Table 1](#molecules-25-03116-t001){ref-type="table"}, [Figure 1](#molecules-25-03116-f001){ref-type="fig"}).

In response to the alcohol-inflamed liver, bilirubin, AST, ALT, and ALP levels showed a significant increase in their levels, 65.88%, 108.53%, 33.05%, and 34.04%, respectively, when compared to the negative control group ([Table 4](#molecules-25-03116-t004){ref-type="table"}). The MDA level showed a significant increase (42.97%), while the GSH and TAC recorded a significant decrease of 27.42% and 38.46%, respectively ([Table 4](#molecules-25-03116-t004){ref-type="table"}). Furthermore, CRP, TNF-α, ICAM-1, and VCAM-1 parameters showed a significant increase in their levels, 86.96%, 98.49%, 114.54%, and 51.72%, respectively, compared to the negative control group ([Table 4](#molecules-25-03116-t004){ref-type="table"}). Treatment of alcohol-inflamed liver rats with crude, defatted, n-hex extracts showed a significant decrease in bilirubin, AST, ALT, ALP, MDA, CRP, TNF-α, VCAM-1, and ICAM levels, as compared to the silymarin-positive control group in all treated groups ([Table 4](#molecules-25-03116-t004){ref-type="table"}) accompanied by a significant increase in the GSH and TAC levels ([Table 4](#molecules-25-03116-t004){ref-type="table"}). The crude extract showed the highest percentage of improvement for AST (143.23%), ALP (48.47%), and MDA (71.07%). Bilirubin was equally improved upon treatment with crude and n-hex extracts (58.11%). On the other hand, the defatted extract showed the highest percentage of improvement for ALT (66.68%), GSH (50.32%), and TNF-α (78.18%) ([Table 4](#molecules-25-03116-t004){ref-type="table"}). The n-hex extract showed the highest percentage of improvement for the TAC (42.30%), CRP (86.20%), and ICAM-1 (96.36%). VCAM-1 showed the highest percentage of improvement with defatted and n-hex extracts (41.37%). These biochemical findings were also simultaneously substantiated with the histopathological observations described before ([Figure 3](#molecules-25-03116-f003){ref-type="fig"}).

In response to the biochemical parameters above and according to the LC--HRESIMS metabolomic profiling, the n-hex fraction contained sterols, triterpenes, and fatty acids ([Table 1](#molecules-25-03116-t001){ref-type="table"}, [Figure 1](#molecules-25-03116-f001){ref-type="fig"}). These metabolites have been shown to interfere mainly with the expression of pro-inflammatory cytokines and adhesion molecules by blocking the NF-κB activity \[[@B36-molecules-25-03116],[@B37-molecules-25-03116],[@B38-molecules-25-03116]\]. We posit this explains the significant effect of the n-hex extract in reducing the serum levels of CRP, TNF-α, VCAM-1, and ICAM ([Table 4](#molecules-25-03116-t004){ref-type="table"}). The defatted extract mainly contained acylated iridoids, flavones, and phenylethanoids, which were mainly acylated with coumaric, P-methoxy cinnamic, or ferulic aromatic acids ([Table 1](#molecules-25-03116-t001){ref-type="table"}, [Figure 1](#molecules-25-03116-f001){ref-type="fig"}). Having surveyed the relevant literature, defatted extract metabolites were also found to interfere with the expression of pro-inflammatory cytokines and interleukins by blocking the NF-κB activity (especially TNF-α), their activity increasing with the number of free phenolic (-OH) groups \[[@B8-molecules-25-03116],[@B34-molecules-25-03116],[@B35-molecules-25-03116]\]. This phenomenon was observed through the increased TNF-α improving level (102.56%) for the defatted extract compared to other treated groups ([Table 4](#molecules-25-03116-t004){ref-type="table"}). Additionally, the various extracts of *Premna odorata* showed potential anti-inflammatory activity which improved the severe liver cell inflammation accompanied by chronic alcohol consumption ([Table 4](#molecules-25-03116-t004){ref-type="table"}).

The significant reduction of MDA levels and enhancement of the TAC and GSH ([Table 4](#molecules-25-03116-t004){ref-type="table"}) in all treated groups reflected the antioxidant activity for *Premna odorata* metabolites, especially verbascoside (**14**). The latter has been reported as an inhibitor of P~450~2E~1~ or CYP~2~E~1~, therefore, blocking the MEOS metabolic pathway besides having free radical scavenging effects \[[@B39-molecules-25-03116]\]. The net results showed the improvement of endogenous scavenging of free radicals and the total antioxidant potential, which preserves the structural integrity of hepatocytes \[[@B7-molecules-25-03116]\]. As a result of the anti-inflammatory and antioxidant activities of the *Premna odorata* extracts, the elevated levels of ALT and AST were markedly reduced, thus suggesting the stabilization of plasma membranes in addition to repairing the hepatocellular damage. Moreover, the decrease of the raised ALP and bilirubin levels indicated the improvement of the biliary dysfunction ([Table 4](#molecules-25-03116-t004){ref-type="table"}) \[[@B7-molecules-25-03116]\].

According to literature, hepatic treatment investigations were conducted on other *Premna* species, including the study of hepatoprotection of alcoholic *Premna esculenta**,** Premna corymbosa, Premna serratifolia*, and *Premna tomentosa* leave extracts after liver induction with CCl~4~. These studies showed significant hepatoprotection by decreasing the activity of serum enzymes, bilirubin, and lipid peroxidation \[[@B40-molecules-25-03116],[@B41-molecules-25-03116],[@B42-molecules-25-03116],[@B43-molecules-25-03116]\]. Moreover, the hepatoprotective role of the ethanol *Premna integrifolia* leave extract on the aflatoxin B~1~-induced toxicity was studied in mice; the study showed the protective effect of *Premna integrifolia* through the restoration of altered hematological indices and liver marker enzymes \[[@B44-molecules-25-03116]\]. The *Premna* genus is a natural source for bioactive metabolites having anti-inflammatory and antioxidant properties which have a direct effect on liver inflammation.

4. Materials and Methods {#sec4-molecules-25-03116}
========================

4.1. Chemicals {#sec4dot1-molecules-25-03116}
--------------

The solvents used in this work were n-hexane (n-hex.; boiling point (b.p.) 60--80 ˚C), dichloromethane (DCM), ethyl acetate (EtOAC), n-butanol (n-but.), ethanol (EtOH), and H~2~O~2~ purchased from El-Nasr Company for Pharmaceuticals and Chemicals, Egypt. All chemicals for kits ([Table 5](#molecules-25-03116-t005){ref-type="table"}) were of a high analytical grade and purchased from Sigma Chemical Co Ltd. (St Louis, MO, USA). All the kits were produced by Biosystems SA Costa Brava 30, Barcelona (Spain), and DiaSys Diagnostic Systems GmbH, Germany.

4.2. Plant Material and Extraction {#sec4dot2-molecules-25-03116}
----------------------------------

*Premna odorata* leaves were collected at the flowering stage in May 2018 from Zoo, Giza, Egypt. The plant was identified by Abd El-Halim A. Mohammed (Horticultural Research Institute, department of Flora and phytotaxonomy Researchers, Dokki, Cairo, Egypt). A voucher specimen (2018-BuPD 45) was deposited at the department of pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Egypt.

The air-dried leaves (3 kg) were collected and air-dried in the darkness for one month. After drying, the leaves were finely powdered using a CM 290 Cemotec™ laboratory grinder (200--230 V, 50--60 Hz, Foss, Denmark). The finely powdered leaves were extracted by maceration without agitation using 70% ethanol (EtOH), (4 L, 3 X, four days each) at room temperature and subsequently concentrated under vacuum at 40 °C using a rotary evaporator (Buchi Rotavapor R-300, Cole--Parmer, Vernon Hills, IL, USA) to afford a 200 g crude extract. A 20 g aliquot was used for all biological evaluations of the crude extract. Another 2 g crude extract was suspended in 4 mL distilled water and successively Kuching-partitioned with solvents of different polarities (n-hex, DCM, EtOAc, and n-but.) for the LC--HRESIMS experiment. The remaining 178 g crude extract was defatted using n-hex (1 L, 3 h, 3 X). The n-hexane extract was dried at 30 °C using a rotary evaporator (Buchi Rotavapor R-300, Cole--Parmer, Vernon Hills, IL, USA) to obtain the 20 g used for all biological evaluations of the n-hex extract. The remaining extract now defatted by n-hex was dried and 20 g were used as the defatted total extract.

4.3. Metabolomic Analysis Procedure {#sec4dot3-molecules-25-03116}
-----------------------------------

The crude extract of *Premna odorata* leaves and the various fractions (n-hexane, DCM, EtOAc, and n-butanol) were subjected to metabolomic analysis using LC--HRESIMS \[[@B45-molecules-25-03116],[@B46-molecules-25-03116]\]. LC--HRESIMS metabolic analyses were done using an ACQUITY Ultra Performance Liquid Chromatography system coupled with a Synapt G~2~-HDMS quadrupole-time-of-flight hybrid mass spectrometer (Waters, Milford, MA, USA). Chromatographic separation was carried out on an ethylene bridged hybrid (BEH) C~18~ column (2.1 × 100 mm, particle size 1.7 µm; Waters, Milford, MA, USA) with a guard column (2.1 × 5 mm, particle size 1.7 µm) and a linear binary solvent gradient of 0--100% eluent B over 6 min at a flow rate of 0.3 mL/min^−1^ using 0.1% formic acid in water (v/v) as solvent A and acetonitrile as solvent B. The injection volume was 2 µL and the column temperature was 40 °C. Electrospray ionization (ESI) in the positive mode was used and the source was operated at 120 °C. The ESI capillary voltage was set to 0.8 kV, the sampling cone voltage was set to 25 V, and nitrogen (at 350 °C, flow rate (FR) 800 L/h) was used as the desolvation gas and the cone gas (FR 30 L/h). The mass range for the TOF--MS was set according to the mass-to-charge ratio (*m/z*) 50--1,200. In MZmine 2.12, the raw data were imported by selecting the ProteoWizard-converted positive files in the mzML format. Ions were detected, followed by a chromatogram builder and a chromatogram deconvolution. The local minimum search algorithm was applied, and isotopes were also identified via the isotopic peaks grouper. The missing peaks were detected using a gap-filling peak finder. An adduct search as well as a complex search were performed. The processed data set was then subjected to molecular formula prediction and peak identification. The positive data set from each of the respective plant extracts were dereplicated against the Dictionary of Natural Products (DNP) database.

4.4. In Silico ADMET Properties for the Crude Extract of Different Premna odorata Metabolites {#sec4dot4-molecules-25-03116}
---------------------------------------------------------------------------------------------

In silico ADMET properties for the metabolites identified by the Premna odorata metabolomics profiling using LC--HRESIMS were defined using the online PreADMET program version 2.0 depending on the 2D structural models drawn in the ChemBioDraw Ultra version 11.0 software (Cambridge Software), including plasma protein binding (PPB), where the drug is considered; chemicals are strongly PPB at ˃ 90% and weakly at ˂ 90%. The blood--brain barrier (BBB); the drug is considered to have high absorption to the CNS ˃ 2.0 BB (Cbrain/Cblood), moderate absorption to the CNS at 2.0\~0.1 BB (Cbrain/Cblood), and low absorption to the CNS at ˂ 0.1 BB (Cbrain/Cblood) \[[@B47-molecules-25-03116]\]. For skin permeability (SP), PreADMET predicts in vitro skin permeability and the result value is given as logKp. Kp (cm/h) is defined as follows: KP =$\ \frac{{km} \times D}{h}$*,* where *Km* is the coefficient of distribution between the stratum corneum and the vehicle, *D* is the average diffusion coefficient (cm^2^/h), and *h* is the thickness of skin (cm) \[[@B48-molecules-25-03116]\]. In human intestinal absorption (HIA) \[[@B49-molecules-25-03116]\], the drug is considered a poorly absorbed compound at 0\~20% HIA, a moderately absorbed compound at 20\~70% HIA, and a well-absorbed compound at 70\~100% HIA. In the Caco-2 cell permeability and Madin--Darby canine kidney (MDCK) cell model \[[@B50-molecules-25-03116],[@B51-molecules-25-03116]\], the drug could generally belong to one of three categories: low permeability ˂ 4 P~Caco−2~ (nm/sec), moderate permeability 4\~70 P~Caco−2~ (nm/sec), and high permeability ˃ 70 P~Caco−2~ (nm/sec). Permeability glycoprotein (Pgp) is an important protein of the cell membrane that pumps many foreign substances out of cells, and it likely evolved as a defense mechanism against harmful substances \[[@B52-molecules-25-03116]\]. Cytochromes P~450~-2C~19~ (CYP~2~C~19~), CYP~2~C~9~, and CYP~3~A~4~ are important cytochrome P~450~ enzymes with a major role in the oxidation of both xenobiotic and endogenous compounds \[[@B53-molecules-25-03116]\]. The Ames test is a simple method of testing mutagenicity of a compound \[[@B54-molecules-25-03116]\]. PreADMET predicts toxicity for TA98, TA100, and TA1535, which are often used in the Ames test. The prediction result is positive or negative. Rodent carcinogenicity is a toxicity that causes cancer in the body. PreADMET predicts the result from its model, which is built upon the data of the National Toxicology Program (NTP) and the United States Food and Drug Administration (US FDA), which are the results of the 2-year-long in vivo carcinogenicity tests of mice and rats. Negative prediction indicates clear evidence of carcinogenic activity and positive prediction shows no evidence of carcinogenic activity.

The hERG (the human Ether-à-go-go-Related Gene) is a gene that codes for a protein known as K~v~11.1, the alpha subunit of a potassium ion channel. This ion channel is best known for its contribution to the electrical activity of the heart. The hERG channel mediates the repolarizing I~Kr~ current in the cardiac action potential, which helps coordinate the heart's beating \[[@B55-molecules-25-03116]\].

4.5. In Vitro Measurement of Total Reactive Oxygen Species (ROS) {#sec4dot5-molecules-25-03116}
----------------------------------------------------------------

### 4.5.1. Cell Lines, Culture Conditions {#sec4dot5dot1-molecules-25-03116}

The Hep G2 human liver cancer cell line was obtained from the American Type Culture Collection, the cells were cultured using Roswell Park Memorial Institute (RPMI 1640 medium supplemented with 10% fetal calf serum, 100 U/mL penicillin, and l00 μg/mL streptomycin) in a humidified atmosphere with 7% CO~2~ and 93% air at 37 °C.

### 4.5.2. Intracellular ROS Levels Quantification {#sec4dot5dot2-molecules-25-03116}

ROS inhibition activities of crude, defatted crude, and n-hex *Premna odorata* extracts were tested against the Hep G2 human liver cancer cell line using the ROS flow cytometry assay \[[@B56-molecules-25-03116]\]. In brief, the cells were placed in a 96-well microtiter plate at a density of 1 × 10^4^ cells per well in a final volume of 100 μL of the culture medium. These cells were treated for 24 h with different *Premna odorata* extracts (groups 3--5) and silymarin (group 6) using 10 µL at 37 °C with 5% CO~2~. After the treatment, the cells were immediately incubated for 24 h at 37 °C \[[@B56-molecules-25-03116]\]. The different groups were then treated with 10 mM 2',7'-dichlorodihydrofluorescein diacetate (H~2~DCF--DA) dissolved in the phosphate buffer saline (PBS) (5.0 mg/mL) at 37 °C for 20 min. The color reaction was stopped by removing the media and adding 100 μL DMSO in each well to dissolve the formed formazan crystals. The incubation at 37 °C resumed for up to 20 min to ensure complete dissolution of crystals. The absorbance was determined at λ~495~ nm using an FLX800 fluorescence microplate reader (BioTEK Instruments, Winooski, VT, USA). H~2~O~2~ was used as the positive control.

4.6. Animal Treatment {#sec4dot6-molecules-25-03116}
---------------------

Female Wistar albino rats (150--170 g) were obtained from the animal house of the National Research Centre, Dokki, Giza, Egypt. The rats were fed using a standard diet and free access to tap water \[[@B57-molecules-25-03116]\]. The rats were housed in polypropylene cages and maintained under controlled conditions of the 12 h of light/12 h of dark cycle with 50% relative humidity at 25 to 30 °C with keeping for two weeks to be acclimatized to the environmental conditions.

4.7. Animal Ethical Statement {#sec4dot7-molecules-25-03116}
-----------------------------

This study was approved by the Institutional Animal Ethics Committee of the National Research Center which stated that animals should not suffer at any stage of experimentation and be maintained in accordance with the Guide for the care and use of laboratory animals (ethical approval No: 012234).

4.8. Acute Toxicity Test {#sec4dot8-molecules-25-03116}
------------------------

Acute toxicity studies were carried out using female Wistar albino rats as per Organization for Economic Cooperation and Development (OECD) guideline 423 (2001). According to the latter, acute oral toxicity refers to the adverse effects occurring as a result of oral administration of a single dose of a substance or multiple doses given within 24 h (overnight). Fasted rats were weighed and divided randomly into five groups containing three rats each. As there was no information regarding the plant being tested, for animal welfare reasons, the OECD recommends using a starting dose of 300 mg/kg b.w. If mortality was not observed after 24 h, the previous procedure was repeated for further groups with higher doses: 1000, 2000, 3000, 4000, and 5000 mg/kg b.w.

4.9. Induction of Alcohol Liver Inflammation and Experimental Design {#sec4dot9-molecules-25-03116}
--------------------------------------------------------------------

Acute alcohol liver inflammation was induced in rats according to Keegan (2013) \[[@B58-molecules-25-03116]\]. In a brief manner, rats received 2% sucrose as the sole source of liquid for three days prior to the initiation of 5% ethanol in 2% sucrose. The ethanol concentration was increased in increments of 5% at intervals of four days to a concentration of 15%. Thereafter, weekly increases were made to a final concentration of 40%. Fresh drinking water/ethanol was provided twice weekly. Sixty female Wistar albino rats were divided into six groups each containing ten rats: group 1: healthy rats (negative control); group 2: untreated rats (positive control) euthanized after thirty days; groups 3--5: rats treated orally through gavages with crude, defatted crude and n-hexane extracts, respectively, in the dose of 500 mg/kg b.w. for thirty days and then euthanized; group 6: rats treated orally through gavages with the silymarin reference drug \[[@B59-molecules-25-03116]\] using the 200 mg/kg b.w. dose for thirty days and then euthanized.

### 4.9.1. Blood Sampling {#sec4dot9dot1-molecules-25-03116}

The blood samples were collected in a clean and dry test tube by puncturing of the sublingual vein. Subsequently, allowing the clotting process to last 10 min, they were centrifuged at 108,669× *g* for serum separation. The serum was stored at −80 °C for further experiments.

### 4.9.2. Biochemical Analysis {#sec4dot9dot2-molecules-25-03116}

The separated serum was used for the following tests: liver function tests: bilirubin was determined according to Walter and Gerade (1970) \[[@B60-molecules-25-03116]\]; AST, ALT were determined according to Reitman and Frankel (1957) \[[@B61-molecules-25-03116]\]; ALP was determined according to Belfield and Goldberg (1971) \[[@B62-molecules-25-03116]\] using bio-diagnostic kits (Egypt); oxidative stress marker and antioxidant tests: MDA was determined according to Santos et al. (1980) \[[@B63-molecules-25-03116]\]; GSH was determined according to Kageyama (1971) \[[@B64-molecules-25-03116]\], and the TAC was determined according to Mclemore et al. (1998) \[[@B65-molecules-25-03116]\]; inflammatory marker and adhesion molecule tests: CRP, TNF-α were determined according to Erhardt et al. (2004) \[[@B66-molecules-25-03116]\] and Perrey et al. (1999) \[[@B67-molecules-25-03116]\], respectively; ICAM-1 and VCAM-1 were determined according to Szarka et al. (2010) \[[@B68-molecules-25-03116]\].

4.10. Statistical Analysis {#sec4dot10-molecules-25-03116}
--------------------------

The pooled data were presented as the means ± standard deviation (SD) for ten rats in each group. The differences between different treatment groups were determined by the ANOVA followed by the Dunnett's test using PASW Statistics^®^ version 18 (Quarry Bay, Hong Kong, China), where an unshared letter is considered significant at *p* ≤ 0.05. $${\%{change}} = \frac{mean~of~negative~control - mean~of~treatment~group}{mean~of~negative~control} \times 100$$ $${\%{improvment}} = \frac{mean~of~positive~control - mean~of~treatment~group}{mean~of~negative~control} \times 100$$

4.11. Histopathological Examination {#sec4dot11-molecules-25-03116}
-----------------------------------

The histological sections of the liver for all experimental groups of rats were taken by adopting the procedure described by Gomori (1941) \[[@B69-molecules-25-03116]\]. Briefly, liver slices were taken from all groups and fixed instantaneously in neutral buffered formalin (10%) for 24 h, then processed in automatic processors, embedded in paraffin wax (melting point 55--41 °C), and paraffin blocks were obtained. Sections of 6 μm thickness were prepared and stained with the hematoxylin and eosin (H&E) stain. The cytoplasm stained shades of pink and red, while the nuclei gave a blue color. The slides were examined and photographed under a light microscope at the ×150 magnification power.

5. Conclusions {#sec5-molecules-25-03116}
==============

To sum up, our results showed 28 metabolites related to iridoids and polyphenolics; they were dereplicated and their biological relevance was correlated. The crude extract showed better activity in normalizing most of the parameters, indicating its capability to improve the inflamed liver in vitro and in vivo through its antioxidant capabilities, which was clear in all the chemical and histological examinations. The in silico ADMET screening study showed great bioavailability and distribution of different components. These findings support the use of these extracts due to the combined effects of these phytochemicals and/or their synergistic interactions as a natural remedy to improve the inflamed liver function.
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![Dereplicated metabolites from the LC--HRESIMS analysis of the crude *Premna odorata* leave extract and fractions.](molecules-25-03116-g001){#molecules-25-03116-f001}

![Reactive oxygen species (ROS) induction by H~2~O~2~ in the Hep G2 human liver cancer cell line: scavenging effects of various *Premna odorata* extracts. The cells were treated with 100 µL and evaluated for ROS production as described in the Materials and Methods. The data (means ± SD) are representative of three independent experiments. Significant difference at *p* ˂ 0.05 versus H~2~O~2~.](molecules-25-03116-g002){#molecules-25-03116-f002}

![Histopathological results of the activity for *Premna odorata* extracts (crude, defatted, and n-hexane) and silymarin in alcohol-inflamed liver female Wistar albino rats using a dose of 500 and 200 mg/kg b.w., respectively (H and E X 400). (**A**) The liver of a rat from group 1 (negative control) showing the negative histological structure of a hepatic lobule. (**B**) The liver of a rat from group 2 (positive control) showing congestion of the central vein and hepatic sinusoids. (**C**) The liver of a rat from group 2 showing cytoplasmic vacuolization of hepatocytes and a portal edema. (**D**) The liver of a rat from group 2 showing focal hepatic necrosis associated with inflammatory cell infiltration. (**E**) The liver of a rat from group 3 (crude extract-treated group) showing necrosis of sporadic hepatocytes. (**F**) The liver of a rat from group 3 showing slight congestion of hepatic sinusoids. (**G**) The liver of a rat from group 4 (defatted extract-treated group) showing slightly hydropic degeneration of hepatocytes. (**H**) The liver of a rat from group 4 showing hydropic degeneration of hepatocytes and focal hepatic necrosis associated with inflammatory cell infiltration. (**I**) The liver of a rat from group 5 (n-hexane-treated group) showing a slightly portal edema. (**J**) The liver of a rat from group 5 showing slightly hydropic degeneration of hepatocytes. (**K**) The liver of a rat from group 6 (silymarin-treated group) showing slightly hydropic degeneration of hepatocytes. (**L**) The liver of a rat from group 6 showing slightly focal hepatic hemorrhage.](molecules-25-03116-g003){#molecules-25-03116-f003}

molecules-25-03116-t001_Table 1

###### 

The liquid chromatography/high-resolution electrospray ionization mass spectroscopy (LC--HRESIMS) dereplication results of the crude *Premna odorata* leave extract and fractions (n-hexane, dichloromethane, ethyl acetate, n-butanol).

  No.      Identified                                                            Source                 MF                t~R~(min.)   *m/z*      Adduct          CE   H    DCM   EtOAC   B
  -------- --------------------------------------------------------------------- ---------------------- ----------------- ------------ ---------- --------------- ---- ---- ----- ------- ----
  **1**    Vitexin                                                               *Premna odorata*       C~21~H~20~O~10~   9.71         433.1361   \[M + H\]^+^    \+                      \+
  **2**    Premnoside A                                                          *Premna odorata*       C~39~H~44~O~20~   11.37        833.2746   \[M + H\]^+^    \+              \+      \+
  **3**    6- O-α- L-(2''-O-trans-caffoyl) rhamnopyranosyl catalpol              *Premna odorata*       C~30~H~38~O~17~   11.98        671.1910   \[M + H\]^+^    \+              \+      \+
  **4**    Daucosterol                                                           *Premna japonica*      C~35~H~60~O~6~    12.33        577.1969   \[M + H\]^+^    \+   \+                 
  **5**    Premnoside D                                                          *Premna odorata*       C~39~H~44~O~19~   12.61        817.2282   \[M + H\]^+^    \+              \+      \+
  **6**    Premnoside H                                                          *Premna odorata*       C~39~H~44~O~18~   13.00        801.2404   \[M + H\]^+^    \+              \+      \+
  **7**    Premnoside C                                                          *Premna odorata*       C~40~H~46~O~19~   13.09        831.2411   \[M + H\]^+^    \+              \+      \+
  **8**    6- O-α- L-(2''-O-trans-p-methoxycinnamoyl) rhamnopyranosyl catalpol   *Premna japonica*      C~31~H~40~O~16~   13.20        669.1634   \[M + H\]^+^    \+              \+      \+
  **9**    Stigmasterol                                                          *Premna odorata*       C~29~H~48~O       13.33        413.2619   \[M + H\]^+^    \+   \+                 
  **10**   Acacetin                                                              *Premna odorata*       C~16~H~12~O~5~    13.60        285.1126   \[M + H\]^+^    \+              \+      
  **11**   Premnoside G                                                          *Premna odorata*       C~39~H~44~O~18~   13.72        801.2404   \[M + H\]^+^    \+              \+      \+
  **12**   6- O-α- L-(4''-O-trans-feruloyl) rhamnopyranosyl catalpol             *Premna japonica*      C~31~H~40~O~17~   13.78        685.2780   \[M + H\]^+^    \+              \+      \+
  **13**   β-sitosterol                                                          *Premna odorata*       C~29~H~50~O       14.19        414.1849   \[M + H\]^+^    \+   \+                 
  **14**   Verbascoside                                                          *Premna odorata*       C~29~H~36~O~15~   14.47        625.1396   \[M + H\]^+^    \+              \+      \+
  **15**   Premnoside F                                                          *Premna odorata*       C~41~H~48~O~18~   14.54        829.2011   \[M + H\]^+^    \+              \+      \+
  **16**   Premnoside E                                                          *Premna odorata*       C~41~H~48~O~18~   14.73        829.2011   \[M + H\]^+^    \+              \+      \+
  **17**   Linolenic acid                                                        *Premna microphylla*   C~18~H~30~O~2~    14.81        277.1807   \[M - H\]^+^    \+   \+                 
  **18**   Diosmetin                                                             *Premna odorata*       C~16~H~12~O~6~    15.09        301.2947   \[M + H\]^+^    \+        \+    \+      
  **19**   Premnaodoroside A                                                     *Premna odorata*       C~42~H~66~O~20~   15.94        891.3561   \[M + H\]^+^    \+        \+            
  **20**   Premnaodoroside B                                                     *Premna odorata*       C~42~H~66~O~19~   16.06        875.2437   \[M + H\]^+^    \+        \+            
  **21**   Premnaodoroside C                                                     *Premna odorata*       C~42~H~64~O~19~   16.12        873.3192   \[M + H\]^+^    \+        \+            
  **22**   Premnoside D                                                          *Premna odorata*       C~40~H~46~O~20~   16.21        847.2782   \[M + H\]^+^    \+              \+      \+
  **23**   Premnaodoroside D                                                     *Premna subscandens*   C~42~H~64~O~20~   17.74        889.2297   \[M + H\]^+^    \+        \+            
  **24**   Β-amyrin                                                              *Premna odorata*       C~30~H~50~O       18.28        465.2018   \[M + K\]^+^    \+   \+                 
  **25**   Luteolin                                                              *Premna odorata*       C~15~H~10~O~6~    18.66        309.2349   \[M + Na\]^+^   \+        \+    \+      
  **26**   Apigenin                                                              *Premna odorata*       C~15~H~10~O~5~    20.82        293.2147   \[M + Na\]^+^   \+              \+      
  **27**   Premcoryoside                                                         *Premna corymbosa*     C~45~H~58~O~24~   21.52        983.4891   \[M + H\]^+^    \+                      \+
  **28**   Arjunolic acid                                                        *Premna microphylla*   C~30~H~48~O~5~    21.64        489.2793   \[M + H}^+^     \+   \+                 

MF: molecular formula, t~R~: retention time, min.: minute, CE: crude extract, H: n-hexane fraction, DCM: dichloromethane fraction, EtOAC: ethyl acetate fraction, B: n-butanol fraction.
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###### 

The predicted absorbance, distribution, metabolism, excretion (ADME) properties of the LC--HRESIMS dereplication metabolites of the crude *Premna odorata* leave extract using the in silico predicts absorption, distribution, metabolism, excretion, and toxicity (PreADMET) method.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.      PPB%         BBB\                  SP\         HIA%        MDCK\       Caco-2\    Pgp Inhibition   CYP-~2~C~19~ Inhibition   CYP-~2~C~9~ Inhibition   CYP-~3~A~4~ Inhibition   CYP-~3~A~4~ Substrate
                        (C~brain~/C~blood~)   (cm/hour)               (nm/sec)    (nm/sec)                                                                                                
  -------- ------------ --------------------- ----------- ----------- ----------- ---------- ---------------- ------------------------- ------------------------ ------------------------ -----------------------
  **1**    61.323656    0.0385273             −4.61128    31.374153   0.5424090   5.48785    No               Inhibitor                 Inhibitor                Inhibitor                Weak

  **2**    54.348583    0.0287162             −3.02912    3.7348170   0.0447556   13.6259    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **3**    33.285061    0.0298880             −4.70662    3.3153240   0.1538230   11.0644    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **4**    100.000000   5.3038700             −2.20420    90.027561   0.1220710   25.2333    Inhibitor        No                        Inhibitor                Inhibitor                Substrate

  **5**    54.577268    0.0305549             −2.97228    8.4947690   0.0455697   14.1947    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **6**    56.739888    0.0342009             −2.91786    19.057599   0.0454732   14.7567    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Substrate

  **7**    48.364678    0.0424033             −2.96634    16.156072   0.0454091   14.0366    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **8**    33.832287    0.06277950            −4.6442     13.170559   0.1289870   12.3956    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **9**    100.000000   19.8938000            −0.717667   100.00000   3.783450    52.3376    Inhibitor        No                        Inhibitor                Inhibitor                Substrate

  **10**   90.917451    0.15030900            −3.36001    93.042708   20.230800   12.7923    No               Inhibitor                 Inhibitor                Inhibitor                No

  **11**   53.912360    0.1319930             −2.9222     52.345314   0.0449026   15.3124    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **12**   32.612262    0.0411953             −4.70477    5.9983830   0.1105100   9.11617    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **13**   100.000000   19.8883000            −0.593439   100.00000   8.8571900   52.3734    Inhibitor        No                        Inhibitor                Inhibitor                Substrate

  **14**   64.288492    0.03167600            −3.5116     7.6711810   0.0450549   11.1087    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **15**   54.629780    0.1252660             −2.92245    52.345571   0.0451432   15.4511    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **16**   53.912360    0.1319930             −2.9222     52.345314   0.0449026   15.3124    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **17**   100.000000   6.16921000            −0.538273   98.273607   74.789700   27.9738    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                No

  **18**   90.160128    0.20108600            −4.13473    88.188263   23.853100   7.02526    No               Inhibitor                 Inhibitor                Inhibitor                No

  **19**   34.413157    0.0284513             −3.29001    1.9433930   0.2328650   16.3835    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Substrate

  **20**   40.461576    0.0298628             −3.70182    4.3580790   0.0841395   17.2768    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Substrate

  **21**   41.088270    0.0302347             −3.26196    5.1422870   0.1599090   15.3574    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Substrate

  **22**   45.368220    0.0328157             −3.02594    7.1270550   0.0447377   12.7477    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Weak

  **23**   34.183542    0.0283962             −3.80436    2.2958830   0.291627    17.4161    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Substrate

  **24**   100.000000   21.2500000            −2.22251    100.00000   0.1749200   46.7500    Inhibitor        No                        Inhibitor                Inhibitor                Substrate

  **25**   99.717233    0.36758200            −4.28017    79.427233   36.520500   4.53973    No               Inhibitor                 Inhibitor                Inhibitor                No

  **26**   97.253409    0.56511300            −4.14570    88.122839   44.302000   10.5468    No               Inhibitor                 Inhibitor                Inhibitor                No

  **27**   37.405289    0.0273879             −2.50822    0.3453560   0.0434853   11.7965    Inhibitor        Inhibitor                 Inhibitor                Inhibitor                Substrate

  **28**   97.049829    0.58860800            −3.57106    91.233319   0.0434480   20.9815    Inhibitor        No                        Inhibitor                Inhibitor                Substrate
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PPB: plasma protein binding; BBB: blood--brain barrier; SP: skin permeability; HIA: human intestinal absorption; MDCK: Madin--Darby Canine Kidney; Pgp: permeability glycoprotein; and CYP: cytochrome P. In PPB, the drug is considered; chemicals are strongly PPB at ˃ 90% PPB and weakly at ˂ 90%. In the BBB, the drug is considered to have high absorption to the CNS at ˃ 2.0 BB (Cbrain/Cblood), middle absorption to the CNS at 2.0\~0.1 BB (Cbrain/Cblood), and low absorption to the CNS at ˂ 0.1 BB (Cbrain/Cblood). For SP, PreADMET predicts in vitro skin permeability and the result value is given as logKp. Kp (cm/hour) is defined as follows: KP =$\ \frac{{km} \times D}{h}$, where *Km* is the coefficient of distribution between the stratum corneum and the vehicle, *D* is the average diffusion coefficient (cm^2^/h), and *h* is the thickness of skin (cm). In HIA, the drug is considered a poorly absorbed compound at 0\~20%, a moderately absorbed compound at 20\~70%, and a well-absorbed compound at 70\~100%. In the Caco-2 cell permeability and the MDCK cell model, the drug could generally belong to one of three categories: low permeability ˂ 4 P~Caco−2~ (nm/sec), moderate permeability 4\~70 P~Caco−2~ (nm/sec), and high permeability ˃ 70 P~Caco−2~ (nm/sec). Pgp is an important protein of the cell membrane that pumps many foreign substances out of cells, and it likely evolved as a defense mechanism against harmful substances. Cytochrome P~450~-2C~19~ (CYP~2~C~19~), CYP~2~C~9~, and CYP~3~A~4~, are important cytochrome P~450~ enzymes with a major role in the oxidation of both xenobiotic and endogenous compounds.
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###### 

Toxicity profile of the LC--HRESIMS dereplication metabolites of *Premna odorata* leaves crude extract using in silico predicts absorption, distribution, metabolism, excretion, and toxicity (PreADMET) method.

  No.      Ames Test       TA100-10RLI   TA100-NA   TA1535-10RLI   TA1535-NA   Carcinogenic for Mice   Carcinogenic for Rats   HERG Inhibition
  -------- --------------- ------------- ---------- -------------- ----------- ----------------------- ----------------------- -----------------
  **1**    Non-mutagenic   −             −          −              −           \+                      −                       High risk
  **2**    Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **3**    Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **4**    Non-mutagenic   −             −          −              −           \+                      −                       Low risk
  **5**    Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **6**    Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **7**    Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **8**    Non-mutagenic   −             −          −              −           \+                      −                       High risk
  **9**    Non-mutagenic   −             −          −              −           \+                      \+                      Low risk
  **10**   Mutagenic       \+            \+         −              −           \+                      \+                      Moderate risk
  **11**   Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **12**   Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **13**   Non-mutagenic   −             −          −              −           \+                      −                       Low risk
  **14**   Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **15**   Non-mutagenic   −             −          −              −           \+                      −                       High risk
  **16**   Non-mutagenic   −             −          −              −           \+                      −                       High risk
  **17**   Mutagenic       −             −          −              \+          \+                      \+                      Moderate risk
  **18**   Mutagenic       −             \+         −              −           \+                      \+                      Moderate risk
  **19**   Mutagenic       −             \+         −              −           \+                      −                       Ambiguous
  **20**   Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **21**   Mutagenic       −             \+         −              −           \+                      −                       Ambiguous
  **22**   Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **23**   Mutagenic       −             \+         −              −           \+                      −                       Ambiguous
  **24**   Non-mutagenic   −             −          −              −           \+                      \+                      Low risk
  **25**   Mutagenic       −             \+         −              −           \+                      \+                      Moderate risk
  **26**   Mutagenic       \+            \+         −              −           \+                      \+                      Moderate risk
  **27**   Non-mutagenic   −             −          −              −           \+                      −                       Ambiguous
  **28**   Non-mutagenic   −             −          −              −           \+                      \+                      Low risk
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###### 

Results of the liver function, oxidative stress marker, antioxidant, inflammatory marker, and adhesion molecule tests measuring the activity of the *Premna odorata* crude, defatted, and n-hex extracts induced in alcohol-inflamed liver female Wistar albino rats according to Keegan (2013) \[[@B23-molecules-25-03116]\] using a dose of 500 mg/kg b.w. for thirty days who were then euthanized (silymarin was used as a reference drug using a 200 mg/kg b.w. dose).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   Groups                                                                                                             
  -------------------- ----------- --------------------- ---------------------- ---------------------- ---------------------- ----------------------- -----------------------
  Bilirubin\           Mean ± SD   0.85 ± 0.05 ^b^       1.41 ± 0.18 ^a^        0.916 ± 0.07 ^b^       0.95 ± 0.05 ^b^        0.916 ± 0.076 ^b^       0.8 ± 0.05 ^b^
  (mg/dl)                                                                                                                                             

  \% change                        65.88                 7.76                   11.76                  7.76                   5.88                    

  \% improvement                                         58.11                  54.11                  58.11                  71.76                   

  AST\                 Mean ± SD   39.00 ± 7.81 ^b^      81.33 ± 21.45 ^a^      25.47 ± 4.50 ^d^       28.33 ± 1.53 ^cd^      32.33 ± 2.08 ^bc^       31.47 ± 3.51 ^bcd^
  (U/I)                                                                                                                                               

  \% change                        108.53                34.20                  27.30                  17.10                  19.31                   

  \% improvement                                         143.23                 133.23                 125.64                 127.84                  

  ALT\                 Mean ± SD   108.47 ± 18.85 ^b^    144.33 ± 25.1 ^a^      77.33 ± 4.42 ^bc^      72.00 ± 2.00 ^bc^      92.47 ± 16.28 ^b^       93.33 ± 5.77 ^b^
  (U/I)                                                                                                                                               

  \% change                        33.05                 28.71                  33.62                  14.75                  13.96                   

  \% improvement                                         61.76                  66.68                  47.81                  47.02                   

  ALP\                 Mean ± SD   173.33 ± 29.29 ^bc^   232.33 ± 2.51 ^a^      148.33 ± 10.40 ^bc^    181.47 ± 7.44 ^b^      185 ± 18.02 ^b^         141.47 ± 2.51 ^c^
  (IU/L)                                                                                                                                              

  \% change                        34.04                 14.42                  4.69                   6.73                   18.27                   

  \% improvement                                         48.47                  29.32                  27.29                  52.42                   

  MDA\                 Mean ± SD   2818.85 ± 200.5 ^c^   4,029.85 ± 200.5 ^a^   2,026.33 ± 52.50 ^d^   2,121.47 ± 91.76 ^d^   2,248.00 ± 141.24 ^d^   3,250.47 ± 416.41 ^b^
  (mmol/l)                                                                                                                                            

  \% change                        42.97                 28.11                  24.73                  20.22                  15.33                   

  \% improvement                                         71.07                  67.21                  63.20                  27.60                   

  GSH\                 Mean ± SD   412.86 ± 56.94 ^bc^   299.16 ± 54.98 ^d^     491.91 ± 27.56 ^c^     506.88 ± 86.32 ^b^     495.46 ± 28.99 ^ab^     411.29 ± 77.11 ^bc^
  (mg/g tissue used)                                                                                                                                  

  \% change                        27.42                 19.15                  22.77                  20.26                  0.24                    

  \% improvement                                         46.60                  50.32                  47.57                  27.18                   

  TAC\                 Mean ± SD   0.26 ± 0.02 ^a^       0.16 ± 0.02 ^b^        0.26 ± 0.02 ^a^        0.26 ± 0.02 ^a^        0.27 ± 0.03 ^a^         0.29 ± 0.02 ^a^
  (mmol/l)                                                                                                                                            

  \% change                        38.46                 0                      0                      3.84                   11.53                   

  \% improvement                                         38.46                  38.46                  42.30                  50.00                   

  CRP\                 Mean ± SD   29.30 ± 2.01 ^b^      54.58 ± 2.18 ^a^       32.47 ± 2.51 ^b^       33.33 ± 1.52 ^b^       29.03 ± 2.74 ^b^        31.20 ± 1.38 ^b^
  (ng/mL)                                                                                                                                             

  \% change                        86.96                 10.34                  13.79                  1.02                   6.48                    

  \% improvement                                         75.86                  72.40                  86.20                  80.34                   

  TNF-α\               Mean ± SD   39.33 ± 2.47 ^bc^     73.03 ± 2.45 ^a^       43.47 ± 2.76 ^bc^      33.47 ± 1.53 ^c^       41.47 ± 2.39 ^bc^       52.41 ± 1.45 ^b^
  (pg/mL)                                                                                                                                             

  \% change                        98.49                 10.25                  15.38                  5.12                   33.74                   

  \% improvement                                         76.92                  102.56                 82.76                  53.84                   

  ICAM-1\              Mean ± SD   5.53 ± 0.47 ^c^       11.81 ± 1.22 ^a^       7.46 ± 1.41 ^b^        6.83 ± 0.77 ^bc^       6.49 ± 0.41 ^bc^        6.43 ± 0.56 ^bc^
  (μg/mL)                                                                                                                                             

  \% change                        114.54                36.36                  23.50                  18.18                  16.30                   

  \% improvement                                         78.18                  90.05                  96.20                  98.18                   

  VCAM-1\              Mean ± SD   2.92 ± 0.12 ^b^       4.46 ± 1.30 ^a^        3.40 ± 0.20 ^b^        3.29 ± 0.23 ^b^        3.22 ± 0.58 ^b^         2.96 ± 0.11 ^b^
  (μg/mL)                                                                                                                                             

  \% change                        51.72                 17.24                  13.79                  13.79                  3.45                    

  \% improvement                                         37.93                  41.37                  41.37                  51.72                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Group 1: negative control group; group 2: alcohol-inflamed liver (positive control group); group 3: crude extract-treated group; group 4: defatted crude extract-treated group; group 5: n-hexane extract-treated group; group 6: silymarin-treated group; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; MDA: malondialdehyde; GSH: glutathione; TAC: total antioxidant capacity; CRP: C-reactive protein; TNF-α: tumor necrosis factor-α; ICAM-1: intercellular adhesion molecule-1; VCAM-1: vascular cell adhesion molecule-1.Pooled data presented as the means ± standard deviation (SD) for ten rats in each group. The differences between various treatment groups determined by the ANOVA followed by the Dunnett's test using PASW Statistics^®^ version 18 (Quarry Bay, Hong Kong), ^a^--^d^: Means with different letters in the same row differs significantly (*p* ≤ 0.05), where an unshared letter is considered significant at *p* ≤ 0.05.
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###### 

Kit reagents used in the different experiments.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Experiment      Kit Reagents
  --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **ROS**         2',7'-dichlorodihydrofluorescein diacetate (H~2~DCF--DA), Roswell Park Memorial Institute (RPMI) 1640 medium, fetal calf serum, penicillin, and streptomycin

  **Bilirubin**   sulfanilic acid, hydrochloric acid, dimethyl sulfoxide

  **AST**         phosphate buffer pH 7.5 (100 mmol/L), aspartate (10 0mmol/L), α-ketoglutarate (2 mmol/L)

  **ALT**         alanine 200 mmol/L, 2,4-dinitrophenyl hydrazine (1 mmol/L)

  **ALP**         standard phenol (1.59 mmol/L), buffer pH 10 (50 mmol/L), phenyl phosphate (5 mmol/L), EDTA (100 mmol/L), 4-aminophenazone (50 mmol/L), potassium ferricyanide (200 mmol/L)

  **MDA**         standard MDA (10 mmol/mL), thiobarbituric acid (25 mmol/L), detergent (3 mmol/L), stabilizer (15 mmol/L)

  **GSH**         DTNB (1 mmol/L)

  **TAC**         sulfuric acid, sodium phosphate, ammonium molybdate

  **CRP**         capture antibody-coated microplate: one plate of 96 wells coated with a rabbit anti-rat CRP antibody\
                  detection antibody/enzyme conjugates (100 x): concentrated horseradish peroxidase (HRP) conjugated to a rabbit anti-rat CRP antibody containing stabilizers and preservative\
                  standard (10 x): rat serum with elevated levels of CRP, wash buffer: powdered phosphate-buffered saline (PBS) with 0.05% Tween-20, TMB substrate: solution containing 3, 3', 5, 5'-tetramethylbenzidine (TMB)\
                  stop solution: diluted phosphoric acid

  **TNF-α**       Rat TNF-α microplates -- 96-well polystyrene microplates (12 strips of 8 wells) coated with a monoclonal antibody specific to rat TNF-α\
                  Rat TNF-α conjugate -- 23 mL/vial of a polyclonal antibody against the rat TNF-α conjugated to horseradish peroxidase with preservatives\
                  Rat TNF-α standard -- 1.5 ng/vial of the recombinant rat TNF-α in a buffered protein base with preservatives, lyophilized\
                  Rat TNF-α control -- the recombinant rat TNF-α in a buffered protein base with preservatives. lyophilized\
                  The concentration range of the rat TNF-α after reconstitution. The assay value of the control should be within the range specified on the label, assay diluent RD1-41 -- 12.5 mL/vial of the buffered protein base with preservatives, calibrator diluent RDS-17 -- 21 mL/vial of the buffered protein base with preservatives, wash buffer concentrate -- 50 mL/vial of a 25-fold concentrated solution of a buffered surfactant with preservatives, color reagent A -- 12.5 mL/vial of the stabilized hydrogen peroxidase, color reagent B -- 12.5 mL/vial of the stabilized chromogen (tetramethylbenzidine)\
                  Stop solution -- 23 mL/vial of a diluted hydrochloric acid solution, plate covers -- adhesive strips

  **VCAM-1**      Pre-coated, ready-to-use 96-well strip plate, plate sealer for 96 wells, standard diluent, assay diluent A, assay diluent B, stop solution, standard, detection reagent A, detection reagent B, TMB substrate, wash buffer (30 x concentrate);

  **ICAM-1**      Pre-coated 96-well strip microplate, wash buffer, stop solution, assay diluent(s), lyophilized standard, biotinylated detection antibody, streptavidin-conjugated HRP, TMB One-Step Substrate
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
